Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8771602 | The Journal of Urology | 2018 | 7 Pages |
Abstract
In patients with NCCN very low and low risk prostate cancer genomic scores did not demonstrate meaningfully significant differences by volume based on clinically established cutoff points. Moreover, genomic scores identified and reclassified men with higher risk disease despite generally acceptable surveillance characteristics in this group according to grade and volume. This suggests that in patients at low risk the tumor biological potential measured by genomics rather than by volume should inform decisions on active surveillance candidacy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Yaw A. Nyame, Dominic C. Grimberg, Daniel J. Greene, Karishma Gupta, Ganesh K. Kartha, Ryan Berglund, Michael Gong, Andrew J. Stephenson, Cristina Magi-Galluzzi, Eric A. Klein,